IQVIA

Research Triangle Park – October 13, 2026 -- IQVIA has selected four Veeva applications (CTMS, eTMF, Study Startup and Site Connect) as enterprise standards for its clinical development studies, extending a partnership that previously covered Veeva's EDC.

IQVIA and Veeva widen the clinical technology tie-up beyond EDC

IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced the expansion on Oct. 13, 2026. The companies say the combined offering is intended to raise trial speed and efficiency, strengthen site centricity and improve decision-making.

All Veeva clinical solutions are also available through IQVIA for sponsors that want a full Veeva technology stack.

Pune, India – September 26, 2026 -- The global AI in Clinical Trials Market is set to more than triple from USD 2 billion in 2025 to USD 7.32 billion by 2034, expanding at a 15.5% compound annual growth rate, according to Maximize Market Research.

Pharmaceutical firms accelerate AI adoption to cut trial delays

Pharmaceutical and biotechnology companies, along with contract research organizations, hospitals and research institutes, are deploying machine learning, natural language processing and deep learning to speed patient screening, cohort selection, trial design and large-scale data analysis. These tools are applied across Phase I, Phase II and Phase III trials for patient recruitment, safety monitoring, drug discovery and personalized medicine.

Hopewell, N.J. – September 19, 2026 -- ProBio, a global contract development and manufacturing organization (CDMO), has struck a strategic collaboration with Kun Tuo, an IQVIA-owned clinical research organization (CRO) in China, to integrate manufacturing and clinical trial execution for advanced therapies.

Partnership links CDMO manufacturing with CRO trial operations in China

The alliance combines ProBio's biologics and cell and gene therapy (CGT) development and manufacturing platform with Kun Tuo's clinical trial management network, targeting faster Investigator-Initiated Trials (IITs) for global biopharma sponsors entering the Chinese market. The integrated offering spans Chemistry, Manufacturing and Controls (CMC), non-clinical studies, and clinical operations under a single coordinated pathway.